#sclerodermaforum 搜尋結果

📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch

🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G

⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E

📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z

👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR

The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8

In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm

Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U

This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…

After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG

📰Our latest #Scleroderma literature highlights, featuring research by Denton, et al. are now live on the #SclerodermaForum. Access these comprehensive slide decks for the latest insights in Scleroderma treatment: ow.ly/VlA750WnvWE

The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y

👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za

🔔Stay informed with our latest #Scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/ufVP50WnvZk

In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum

Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum

Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY

🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug

🔎Discover the newest findings in #Scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/tPqL50Wnw2Z

💡Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/q0fn50Wnuhz

🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G

📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch

👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR

📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z

👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za

The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y

⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E

Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U

📰Our latest #Scleroderma literature highlights, featuring research by Denton, et al. are now live on the #SclerodermaForum. Access these comprehensive slide decks for the latest insights in Scleroderma treatment: ow.ly/VlA750WnvWE

🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug

After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG

The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8

Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum

In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm

In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum

Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY

This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…